NCT06827717 2025-05-31
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06971211 2025-05-14
PARTOM
First Hospital of China Medical University
Phase 2 Recruiting
NCT05894018 2025-05-13
RAFAS-001
Sun Yat-sen University
Phase 2 Recruiting
NCT06541314 2024-11-27
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06516445 2024-07-24
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06413992 2024-05-14
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05759546 2024-02-06
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06074692 2023-10-31
PRIMA
Ruijin Hospital
Phase 2 Recruiting
NCT05761470 2023-03-09
IMPARP
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Recruiting